---
document_datetime: 2023-09-21 19:44:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_en.pdf
document_name: fasenra-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7633635
conversion_datetime: 2025-12-20 08:48:11.189047
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging                          | Content (concentration)   | Pack size            |
|------------------|-------------------|------------|------------------------|---------------------------|----------------------------------------------|---------------------------|----------------------|
| EU/1/17/1252/001 | Fasenra           | 30 mg      | Solution for injection | Subcutaneous use          | pre-filled syringe (glass)                   | 1 ml (30 mg/ml)           | 1 pre-filled syringe |
| EU/1/17/1252/002 | Fasenra           | 30 mg      | Solution for injection | Subcutaneous use          | pre-filled syringe (glass) in pre-filled pen | 1 ml (30 mg/ml)           | 1 pre-filled pen     |